News
QURE
5.20
-3.88%
-0.21
Weekly Report: what happened at QURE last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at QURE last week (0311-0315)?
Weekly Report · 03/18 09:10
Weekly Report: what happened at QURE last week (0304-0308)?
Weekly Report · 03/11 09:10
AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
B of A Securities boosted the price target for Li Auto Inc. (NASDAQ:LI) to $60. Barclays increased Advanced Micro Devices, Inc. Price target from $200 to $235 on Friday. TD Cowen maintained an Outperform rating for MasTec. Needham increased the price targets for HashiCorp and Dollar Tree.
Benzinga · 03/04 12:56
uniQure Price Target Cut to $7.00/Share From $10.00 by Mizuho
Dow Jones · 03/04 12:22
uniQure Is Maintained at Neutral by Mizuho
Dow Jones · 03/04 12:22
Weekly Report: what happened at QURE last week (0226-0301)?
Weekly Report · 03/04 09:10
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
UniQure N.V. Shares have fallen 12% since its annual report. The company reported a loss of US$6.59 per share in its latest quarter. Revenues were a bright spot, with the company posting a rise of 4.8% to US$16m. The consensus of 14 analysts is for revenues to grow by 266% in 2024. However, the consensus price target for the company has fallen by 25% following the results.
Simply Wall St · 03/03 12:03
Positive Outlook for uniQure Backed by Strong Gene Therapy Pipeline and Strategic Advancements
TipRanks · 03/01 17:05
uniQure Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
UniQure's revenue exceeded analyst estimates by 6.7%. The company's shares are down 8.4% from a week ago. Revenue is forecast to grow 42% p.a. In the next 3 years. The company reported a loss of US$308.5m for the quarter.
Simply Wall St · 03/01 10:03
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), uniQure (QURE) and RegenXBio (RGNX)
TipRanks · 03/01 06:01
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Butterfly Network, Inc. Shares dipped 21.7% to $1.1588 on Thursday. The company reported mixed fourth-quarter financial results. Enveric Biosciences gained 177.1% in Thursday's mid-day session. Volcon shares rose 55.4% after surging around 39% on Wednesday.
Benzinga · 02/29 19:00
uniQure Price Target Cut to $8.00/Share From $63.00 by Goldman Sachs
Dow Jones · 02/29 16:20
uniQure Cut to Neutral From Buy by Goldman Sachs
Dow Jones · 02/29 16:20
Goldman Sachs Downgrades uniQure to Neutral, Lowers Price Target to $8
Benzinga · 02/29 16:09
Maintaining Hold on uniQure: Balancing Long-Term Potential Against Near-Term Uncertainties
TipRanks · 02/29 13:55
RBC Capital Remains a Buy on uniQure (QURE)
TipRanks · 02/29 12:22
Maintaining Hold on uniQure Amid Regulatory Uncertainty and Financial Considerations
UniQure NV engages in the research, development, and commercialization of gene therapies. Wells Fargo analyst Yanan Zhu maintained a Hold rating on uniQure (QURE – Research Report) and set a price target of $14.00. Zhu is a 5-star analyst with an average return of 22.2%.
TipRanks · 02/29 10:43
A New Cause for Concern: uniQure N.V. Adds a New Innovation / R&D Risk
TipRanks · 02/29 06:02
Buy Rating Affirmed for uniQure: Promising Gene Therapy Pipeline and Solid Financial Outlook
TipRanks · 02/28 17:45
More
Webull provides a variety of real-time QURE stock news. You can receive the latest news about Uniqure through multiple platforms. This information may help you make smarter investment decisions.
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.